Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
Beyond obesity drugs, Eli Lilly's pipeline includes 11 obesity-related treatments and ambitious plans to develop therapies for Alzheimer's, ALS, and other neurological conditions. CEO Eli Lilly and Co (NYSE:LLY) is making a major move with a $4.5 billion investment to create the Lilly Medicine Foundry, a new research and manufacturing facility.
禮來（紐交所: LLY）正在進行一項重大舉措，投資45億美元建立禮來醫藥鑄造廠，一個新的研究和製造設施。
The goal? To bolster its drug pipeline and develop faster, more efficient ways to bring treatments to market. This move builds on the massive success of its GLP-1 drugs, Mounjaro and Zepbound, which are revolutionizing the obesity treatment landscape and are projected to bring in nearly $19 billion in 2024.
目標是加強其藥物管道，開發更快，更有效的方式將治療方法推向市場。此舉建立在其GLP-1藥物Mounjaro和Zepbound的巨大成功基礎上，這些藥物正在改變肥胖治療領域，並預計將在2024年帶來近190億美元的收入。
From Molecules To Medicines, Says CEO Ricks
首席執行官裏克斯表示：「從分子到藥物。」
These drugs have quickly become some of the most talked-about products in the weight-loss market, alongside competitors like Novo Nordisk AS's (NYSE:NVO) Ozempic and Wegovy.
這些藥物迅速成爲減肥市場上最受關注的產品之一，與諾華諾德（紐交所:NVO）的Ozempic和Wegovy等競爭對手並駕齊驅。
Beyond obesity drugs, Eli Lilly's pipeline includes 11 obesity-related treatments and ambitious plans to develop therapies for Alzheimer's, ALS, and other neurological conditions. CEO David Ricks emphasized the facility's role in scaling innovative molecules into life-saving medicines: "The idea is to take molecules from a bench in a lab to scaled for medicines in a pharmacy, and this research and development site will do that work."
除了肥胖藥物，禮來的管道中還包括11種與肥胖有關的治療方法，並着重計劃開發治療阿爾茨海默氏病、ALS和其他神經系統疾病的療法。首席執行官大衛·裏克斯強調該設施在將創新分子擴展爲拯救生命藥物中的作用：「這個設想是將實驗室裏的分子擴展爲藥房裏的藥物，而這個研發基地將完成這項工作。」
Read Also: Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
閱讀更多：禮來投資45億美元建立新的醫藥鑄造廠，實現先進藥物製造以推動美國製藥界的發展。
Eli Lilly Stock Chart Suggests Near-Term Headwinds
禮來股票走勢圖表顯示短期面臨逆風。
From a stock perspective, Eli Lilly has had a fantastic year, posting gains of 49% year-to-date and over 64% in the last 12 months.
從股票角度來看，禮來今年表現出色，年初至今漲幅達49%，過去12個月漲幅超過64%。
However, the technical signals suggest some headwinds in the near term.
然而，技術信號表明在短期內存在一些阻力。
Chart created using Benzinga Pro
使用Benzinga Pro創建的圖表
Eli Lilly stock is trading below key short-term moving averages, including the eight-, 20-, and 50-day simple moving averages (SMA), which traditionally signal a short-to-medium-term bearish outlook. However, the stock trades well above the 200-day SMA, suggesting the long-term remains bullish.
Eli Lilly股價低於關鍵短期移動平均線，包括八天、20天和50天簡單移動平均線（SMA），傳統上預示着短到中期的看淡前景。然而，該股價遠高於200天SMA，表明長期仍然看好。
Chart created using Benzinga Pro
使用Benzinga Pro創建的圖表
The MACD (Moving Average Convergence/Divergence) indicator is negative at 6.28, reinforcing short-term selling pressure. The RSI (Relative Strength Index) lies in neutral territory at 40.89.
MACD（移動平均線收斂/發散）指標爲6.28，加強了短期的賣壓。RSI（相對強弱指數）處於40.89的中立領域。
Yet, long-term investors might still see potential in the stock. With a 200-day moving average of $794.34, Eli Lilly could remain a solid investment for the future, particularly as its obesity drugs gain further market share.
然而，長期投資者仍然可能看到該股票的潛力。以794.34美元的200天移動平均線來看，Eli Lilly可能仍然是未來穩健投資，特別是隨着其肥胖藥物進一步獲得市場份額。
While some volatility may persist in the short term, the long-term potential remains strong as Lilly continues to invest in its drug development pipeline.
儘管短期內可能會有一些波動，但隨着禮來繼續投資於其藥物研發管道，長期潛力仍然強勁。
- Eli Lilly Nears First Trillion Dollar Pharma Title, But Investors Caution Amid Sky-High Valuation
- 禮來公司接近首個萬億美元藥品行業市值稱號，但投資者在估值飆升之際表示謹慎。
Photo: Shutterstock
Photo: shutterstock
